Abpro Holdings, Inc.
ABPO · OTCMCIK 1893219fmd_10BFQCFQSZDNZ9Y7PDPVYJQ0SPManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2021 to Jun 30, 2026, 19 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | – | 0 | 0 | – |
| Research and development | – | 4 | 3 | 1 |
| Total operating expenses | – | 12 | 10 | 8 |
| Operating income | (2) | (12) | (10) | (8) |
| Interest expense | – | 0 | 0 | 1 |
| Interest and investment income | – | 0 | 0 | 0 |
| Other non-operating income (expense) | 4 | 0 | 3 | 6 |
| Income before taxes | 2 | (12) | (7) | – |
| Income tax expense | 1 | 1 | – | – |
| Net income from continuing operations | 1 | (13) | – | – |
| Net income | 1 | (12) | (7) | (3) |